Methods of use for peroxynitrite decomposition catalysts, pharmaceutical compositions therefor

• US 6,245,758 B1
• Filed: 09/09/1996
• Issued: 06/12/2001
• Est. Priority Date: 05/13/1994
• Status: Expired due to Term

• Current Assignee: Pharmacia Corporation (Pfizer Inc.)
• Original Assignee: Pharmacia Corporation (Pfizer Inc.)
• Inventors: Stern, Michael K., Salvemini, Daniela
• Primary Examiner(s): Raymond, Richard L.
• Assistant Examiner(s): Sripada, Pavanaram K
• Application Number:
  US08/709,788
• Time in Patent Office: 1,737 Days
• Field of Search: 514/501, 514/502, 514/184, 514/185, 540/145, 540/122, 540/470
• US Class Current: 514/185
• CPC Class Codes: A61K 31/135 having aromatic rings , e.g. ketamine, nortriptyline methadone A61K31/137
• CPC Class Codes: A61K 31/28 Compounds containing heavy metals
• CPC Class Codes: A61K 31/295 Iron group metal compounds
• CPC Class Codes: A61K 31/395 having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
• CPC Class Codes: A61K 31/40 having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
• CPC Class Codes: A61K 31/44 Non condensed pyridines; Hydrogenated derivatives thereof
• CPC Class Codes: A61K 31/555 containing heavy metals, e.g. hemin, hematin, melarsoprol

Abstract

The present invention provides a method for the treatment of diseases by the decomposition of peroxynitrite, preferably decomposition to benign products, comprising the use of a complex which is a selected ligand structure providing a complexed metal such as Mn, Fe, Ni and V transition metals. The method of use, as well as novel pharmaceutical compositions therefor, are for the treatment of diseases advantageously affected by decomposition of peroxynitrite ed at a rate over the natural background rate of decay of peroxynitrite in humans suffering from the disease which comprises administration of an amount of a complex, in dosage unit form, which is effective for such acceleration of the decomposition of peroxynitrite .

Claims

1. A method of treating a medical condition which is advantageously affected by the accelerated decomposition of peroxynitrite in a subject having such condition comprising administering to the subject a metal complex which is a peroxynitrite decomposition catalyst.

2. A method of claim 1 wherein the disease is ischemic reperfusion, a side effects from drug treatment of cancer, inflammation, sepsis, stroke, multiple sclerosis or parkinson'"'"'s disease.

3. A method of claim 2 wherein the disease-or condition is acute or chronic inflammation.

4. A method of claim 2 wherein the disease is sepsis.

5. A method of claim 2 wherein the disease is stroke.

6. A method of claim 2 wherein the disease is ischemic reperfusion.

7. A method of claim 1 wherein the compound is a ligand structure of a metal which is selected from the group consisting of Mn, Fe, Ni and V.

8. A method of claim 7 wherein the ligand is a macrocyclic with a metal which is Mn, Fe or Ni.

9. A method of claim 4 wherein the ligand is a porphyrin containing metal.

11. A method of claim 1 wherein the metal complex is of the formula

wherein

R₃, R₆, R₉ or R₁₂ are independently selected a group consisting of H, alkyl, alkenyl, CH₂COOH, phenyl, pyridinyl, and N-alkylpyridyl such that phenyl, pyridinyl and N-alkylpyridyl are

which are attached at a carbon atom, and

wherein

phenyl is optionally substituted by halogen, alkyl, aryl, benzyl, COOH, CONH₂, SO₃H, NO₂, NH₂, N(R)₃₊, NHCOR′

wherein R is hydrogen, alkyl, aryl, alkaryl and R′

is alkyl;

pyridinyl is optionally substituted by halogen, alkyl, aryl, benzyl, COOH CONH₂, SO₃H, NO₂, NH2, N(R)₃₊, or NHCOR′

wherein R and R′

are as defined above; and

N-alkylpyridine ring is optionally substituted by halogen, alkyl, aryl, benzyl, COOH, CONH₂, SO₃H, NO₂, NH₂, N(R)₃₊ or NHCOR′

wherein R and R′

are as defined above;

R₁, R₂, R₄, R₅, R₇, R₉, R₁₀, or R₁₁ are independently selected a group consisting of H, alkyl, alkenyl, carboxyalkyl, Cl, Br, F, NO₂, hydroxyalkyl, and SO₃H or R₁R₂ can be taken together to form a ring of from 5 to 8 carbons;

X and Y are ligands or charge-neutralizing anions which are derived from any monodentate or polydentate coordinating ligand or ligand system or the corresponding anion thereof and are independently selected from the group consisting of halide, oxo, aquo, hydroxo, alcohol, phenol, dioxygen, peroxo, hydroperoxo, alkylperoxo, arylperoxo, ammonia, alkylamino, arylamino, heterocycloalkyl amino, heterocycloaryl, amino, amine oxides, hydrazine, alkyl hydrazine, aryl hydrazine, nitric oxide, cyanide, cyanate, thiocyanate, isocyanate, isothiocyanate, alkyl nitrile, aryl nitrile, alkyl isonitrile, aryl isonitrile, nitrate, nitrite, azido, alkyl sulfonic acid, aryl sulfonic acid, alkyl sulfoxide, aryl sulfoxide, alkyl aryl sulfoxide, alkyl sulfenic acid, aryl sulfenic acid, alkyl sulfinic acid, aryl sulfinic acid, alkyl thiol carboxylic acid, aryl thiol carboxylic acid, alkyl thiol thiocarboxylic acid, aryl thiol thiocarboxylic acid, alkyl carboxylic acid, aryl carboxylic acid, urea, alkyl urea, aryl urea, alkyl aryl urea, thiourea, alkyl thiourea, aryl thiourea, alkyl aryl thiourea, sulfate, sulfite, bisulfate, bisulfite, thiosulfate, thiosulfite, hydrosulfite, alkyl phosphine, aryl phosphine, alkyl phosphine oxide, aryl phosphine oxide, alkyl aryl phosphine oxide, alkyl phosphine sulfide, aryl phosphine sulfide, alkyl aryl phosphine sulfide, alkyl phosphonic acid, aryl phosphonic acid, alkyl phosphinic acid, aryl phosphinic acid, alkyl phosphinous acid, aryl phosphinous acid, phosphate, thiophosphate, phosphite, pyrophosphite, triphosphate, hydrogen phosphate, dihydrogen phosphate, alkyl guanidino, aryl guanidino, alkyl aryl guanidino, alkyl carbamate, aryl carbamate, alkyl aryl carbamate, alkyl thiocarbamate, aryl thiocarbamate, alkyl aryl thiocarbamate, alkyl dithiocarbamate, aryl dithiocarbamate, alkyl aryl dithiocarbamate, bicarbonate, carbonate, perchlorate, chlorate, chlorite, hypochlorite, perbromate, bromate, bromite, hypobromite, tetrahalomanganate, tetrafluoroborate, hexafluorophosphate, hexafluoroanitmonate, hypophosphite, iodate, periodate, metaborate, tetraaryl borate, tetra alkyl borate, tartrate, salicylate, succinate, citrate, ascorbate, saccharinate, amino acid, hydroxamic acid, thiotosylate, and anions of ion exchange resins;

with the proviso that when the X and Y containing complex has a net positive charge then Z is a counter ion which is independently X or Y, or when the X and Y containing complex has net negative charge then Z is a counter ion selected from a group consisting of alkaline and alkaline earth cations, organic cations such as alkyl or alkylaryl ammonium cations; and

M is selected from the group consisting of Mn, Fe, Ni and V;

wherein

R′

is CH or N;

R₂, R₂, R₃, R₄, R₅, R₆, R₇, R₈, R₉, R₁₀, R₁₁, R₁₂, R₁₃, R₁₄, R₁₅, and R₁₆ are independently selected from a group consisting of H, SO₃H, COOH, NO₂, NH₂, and N-alkylamino;

X, Y, Z and M are as defined above;

wherein

R₁, R₅, R₉, and R₁₃ are independently a direct bond or CH₂;

R₂, R₂′

, R₄, R₄′

, R₆, R₆′

, R₈, R₈′

, R₁₀, R₁₀′

, R₁₂, R₁₂′

, R₁₄, R₁₄′

, R₁₆, R₁₆′

are independently H or alkyl;

R₃, R₇, R₁₁, R₁₅ are independently H or alkyl;

X, Y, Z and M are as defined above;

wherein

R₁, R₅, R₈, and R₁₂ are independently a direct bond or CH₂;

R₂, R₂′

,R₄, R₄′

,R₆, R₆′

, R₇, R₉, R₉′

, R₁₁, R₁₁′

, R₁₃, R₁₃′

, R₁₄ are independently H or alkyl;

R₃ and R₁₀ are independently H or alkyl;

X, Y, Z and M are as defined above;

wherein

R₁, R₄, R₈, R₁₂ are independently a direct bond or CH₂;

R₂, R₂′

, R₃, R₅, R₅′

, R₇, R₇′

, R₁₁, R₁₁′

, R₁₃, R₁₃′

, R₁₄ are independently H or alkyl;

R₁₀ is H or alkyl;

X, Y, Z and M are as defined above;

wherein

R₁, R₄, R₇ and R₁₀ are independently a direct bond or CH₂;

R₂, R₂′

, R₃, R₅, R₅′

, R₆, R₈, R₈′

, R₉, R₁₁, R₁₁′ and

R₁₂ are independently H or alkyl;

X, Y, Z and M are as defined above;

wherein

R₁, R_{4, R8} and R₁₁ are independently a direct bond or CH2;

R₂, R₃, R₃′

, R₅, R₅′

, R₇, R₇′

, R₉, R₁₀, R₁₀′

, R₁₂, R₁₂′ and

R₁₃ are independently H or alkyl;

R₆ is hydrogen or alkyl;

X, Y, Z and M are as defined above;

wherein

R₁, R₄, R₇ and R₁₀ are independently H or alkyl;

R₂, R₃, R₃′

, R₅, R₅′

, R₆, R₈, R₉, R₉′

, R₁₁, R₁₁′ and

R₁₂ are independently H or alkyl;

X, Y, Z and M are as defined above;

wherein

R₁, R₃, R₄ and R₆ are independently H or alkyl;

R2 and 5 are independently selected from the group consisting of H, alkyl, SO₃H, NO₂, NH₂, halogen, COOH, N(R)₃₊ wherein R is as defined above;

X, Y, Z and M are as defined above;

wherein

R₁, R₂, R₃, R₄ are independently selected from the group consisting of H, alkyl, SO₃H, NO₂, NH₂, halogen, COOH and N(R)₃₊ wherein R is as defined above;

X, Y, Z and M are as defined above;

wherein

R1, R1′

, R2, R2′

, R3, R3′

, R4, R4′

, R5, R5′

, R6, R6′

, R7 and R7′

are independently selected from a group consisting of H, alkyl, alkoxy, NO₂, aryl, halogen, NH₂, SO₃H, and R₆, R₆′

, R₇ and R₇′

may each be taken together with one other of R₆, R₆′

, R₇ and R₇′

to form a cyclic group, preferably a 6 carbon cycloalkyl group;

M¹ is Fe, Ni or V;

X, Y and Z are as defined above.

12. A method of claim 11 wherein the metal complex is structure I of the formula

wherein R₁,R₂, R₃,R₄, R₅,R₆, R₇, R₈, R₉, R₁₀, R₁₁, R₁₂, M, X, Y and Z are as defined for Structure I in claim 11.

14. A method of claim 11 wherein the metal complex is Structure III A, IIIB, IIIC, IIID, IIIE, or IIIF of the formula as defined above.

15. A method of claim 11 wherein the metal complex is Structure IIIG or IIIIH of the formula as defined above.

16. A method of claim 11 wherein the metal complex is Structure IV of the formula

wherein

R₁, R₁′

, R₂, R₂′

, R₃, R₃′

, R₄, R₄′

, R₅, R₅′

, R₆, R₆′

, R₇, R₇′

, X, Y, Z and M¹ are as defined above.

17. A method of claim 11 wherein M is Fe.

18. A method of claim 11 wherein M is Ni.

19. A method of claim 11 wherein M is V.

20. A method of claim 11 wherein M and M¹ are Mn.

21. A method of claim 12 wherein M is Fe.

22. A pharmaceutical composition in dosage unit form for the treatment of a disease in humans advantageously affected by decomposition of peroxynitrite at a rate over the natural background rate of decay of peroxynitrite in humans suffering from the disease comprising, per dosage unit, an effective amount of a metal complex for the decomposition of peroxynitrite wherein the metal complex is as defined in claim 11.

10. A pharmaceutical composition in dosage unit form for the treatment of a disease in humans advantageously affected by decomposition of peroxynitrite at a rate over the natural background rate of decay of peroxynitrite in humans suffering from the disease comprising, per dosage unit, an amount of a metal complex effective for the decomposition of peroxynitrite.

13. A method of claim 11 wherein the metal complex is structure II of the formula

wherein R1, R2, R3, R4, R5, R6, R7, R8, R9, R10, R11, R12, R13, R14, X, Y, M and Z are as defined for Structure II in claim 10.